Growth Metrics

Novartis Ag (NVS) Operating Leases (2019 - 2026)

Novartis Ag's Operating Leases history spans 8 years, with the latest figure at $271.0 million for Q1 2026.

  • On a quarterly basis, Operating Leases rose 11.98% to $271.0 million in Q1 2026 year-over-year; TTM through Mar 2026 was $271.0 million, a 11.98% increase, with the full-year FY2025 number at $263.0 million, up 11.91% from a year prior.
  • Operating Leases hit $271.0 million in Q1 2026 for Novartis Ag, up from $263.0 million in the prior quarter.
  • Over the last five years, Operating Leases for NVS hit a ceiling of $1.6 billion in Q2 2025 and a floor of -$12.0 million in Q1 2022.
  • Historically, Operating Leases has averaged $521.4 million across 5 years, with a median of $248.0 million in 2022.
  • Biggest five-year swings in Operating Leases: plummeted 104.3% in 2022 and later soared 2191.67% in 2023.
  • Tracing NVS's Operating Leases over 5 years: stood at $23.0 million in 2022, then surged by 534.78% to $146.0 million in 2023, then skyrocketed by 60.96% to $235.0 million in 2024, then grew by 11.91% to $263.0 million in 2025, then increased by 3.04% to $271.0 million in 2026.
  • Business Quant data shows Operating Leases for NVS at $271.0 million in Q1 2026, $263.0 million in Q4 2025, and $264.0 million in Q3 2025.